USD 15.2 billion
Report ID: SQMIG35I2261 | Region: Global | Published Date: October, 2023 | Pages: 157 | Tables: 60 | Figures: 75
Global Idiopathic Pulmonary Fibrosis Treatment Market size was valued at USD 15.2 billion in 2021 and is poised to grow from USD 16.13 billion in 2022 to USD 25.96 billion by 2030, at a CAGR of 6.13% during the forecast period (2023-2030).
The global idiopathic pulmonary fibrosis treatment market has experienced significant growth in recent years. The primary reason behind the market growth is growing population, and rising awareness of diseases. Idiopathic pulmonary fibrosis(IPF) is the most common type of pulmonary fibrosis. It’s a disease that causes scarring of the lungs. Scarring causes difficulty in the lungs and makes it difficult to breathe. The landscape of treatment for idiopathic pulmonary fibrosis includes pharmacological interventions, such as Nintedanib and Pirfenidone, which are approved by regulatory bodies for showing progress in disease. In addition, lung transplantation is considered as a viable treatment option for eligible patients in the end stage of this pulmonary fibrosis. During past years, there has been a surge in R&D activities that lead to the emergence of potential therapeutic targets and promising drug entrants. Moreover, the market is also experiencing growth by key market player’s expertise. Collaborations and partnerships between research institutes and pharmaceutical companies to accelerate the development of effective treatment options.
Global Market Size
USD 15.2 billion
To get more reports on the above market click here to Buy The Report
Global Idiopathic Pulmonary Fibrosis Treatment Market is segmented on the basis of type, distribution channel and region. By type, the market is segmented into Pirfenidone and Nintedanib. By distribution channel, it is segmented into hospital pharmacies, retail pharmacies and online providers. By region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Analysis By Type
The largest market segment is pirfenidone segment in the idiopathic pulmonary fibrosis treatment market. Pirfenidone is an anti-fibrotic agent that acts as an anti-inflammatory and antioxidant as well. Additionally, it has been approved by regulatory authorities and is widely used as a standard treatment option for idiopathic pulmonary fibrosis patients. This segment has established efficiency in slowing down the decline in lung function and improving the survival rates of patients that make it the dominating segment in the market.
On the other hand, the Nintedanib segment is experiencing rapid growth, considered as the fastest growing segment in the global idiopathic pulmonary fibrosis treatment market. Nintedanib is in a class of treatments called kinase inhibitors. It works by blocking the action of enzymes involved in affecting fibrosis. Nintedanib has surged in demand and is rapidly accepted due to its favorable safety profile. Nintedanib is a treatment and medication used to slow the rate of decrease in lung function in adults with systemic sclerosis-associated interstitial lung disease.
Analysis By Distribution channel
The dominating segment by distribution channel is hospital pharmacies in the global idiopathic pulmonary fibrosis treatment market. Hospital pharmacies segment plays a crucial role in providing pharmaceutical products and solutions to idiopathic pulmonary fibrosis patients within the hospital and clinics. The pharmacies have direct access to specialized medications such as pirfenidone and nintedanib, which are mostly used in idiopathic pulmonary fibrosis treatment. Hospital pharmacies segment ensure the availability of these treatments and provide professional guidance on its proper usage and administration.
The fastest growing segment in this market is online providers. The increasing adoption of digital platforms and e-commerce, online providers segment has seen significant growth in recent years. These platforms offer a wide range of idiopathic pulmonary fibrosis treatment options including Nintedanib and Pirfenidone. Additionally, this segment offers doorstep delivery particularly beneficial for patients. The growing trend of telemedicine considerations have contributed to the growth of the online providers segment in the market.
To get detailed analysis on other segments, Request For Sample Report
North America dominated the Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market based on region. North America has a strong market presence due to factors such as high prevalence of IPF, well-established healthcare infrastructure, advanced diagnostic capabilities, and availability of approved treatment options. Additionally, robust research and development activities, collaborations between academia and industry, and favorable reimbursement policies contribute to the dominant position of North America in the market. The region is also home to key pharmaceutical companies involved in IPF treatment development and commercialization, further consolidating its leading position.
The Asia Pacific region is experiencing growth in various factors such as a large patient pool, increasing awareness about idiopathic pulmonary fibrosis that enhances healthcare infrastructures, and rising healthcare costs. The region has witnessed a growing geriatric population disposed to idiopathic pulmonary fibrosis. In addition, the increasing focus on early diagnosis and treatment as well as the introduction of innovative therapies drive the market growth in Asia Pacific. Moreover, in this region there are so many key market players who play a significant role in the global idiopathic pulmonary fibrosis treatment market by collaborating and partnerships. These factors are enhancing the growth of Asia Pacific in this market.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing prevalence of IPF
One of the key drivers of the Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market is the increasing prevalence of IPF. The rising incidence of IPF globally, particularly among the aging population, is driving the demand for effective treatment options. As the number of diagnosed IPF cases continues to grow, there is a greater need for pharmaceutical interventions and therapies that can slow down disease progression and improve patients' quality of life.
High treatment costs
Speak to one of our ABIRAW analyst for your custom requirements before the purchase of this report
The global idiopathic pulmonary fibrosis market is described by strong rivalry among key players striving to capture a significant market share. Leading companies are consistently engaged in research and development, product innovation, strategic partnerships, technological advancement and product development to maintain their competitive edge. These industry giants leverage their widespread portfolios to offer a range of solutions, integrating management, and techniques of treatments.
Top Player’s Company Profile
GNI Group Ltd
F. Hoffmann-La Roche Ltd
Shiongi co Ltd
Actelion Pharmaceuticals Ltd
Galecto Biotech AB
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyzes the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
According to our Global Idiopathic Pulmonary Fibrosis Treatment Market analysis, The Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market is witnessing significant growth driven by factors such as increasing prevalence of IPF, a growing geriatric population, and rising awareness about the disease. The market is dominated by treatments like pirfenidone and nintedanib, which have shown efficacy in slowing down disease progression. The market is segmented based on distribution channels, with hospital pharmacies being the dominant segment and online providers emerging as the fastest-growing segment. North America holds a dominant position in the market, while Asia Pacific is the fastest-growing region. Key drivers include the increasing prevalence of IPF, while the high treatment costs act as a restraint. The market is characterized by intense competition, with companies focusing on research and development, strategic collaborations, and acquisitions. Personalized medicine and precision therapeutics are key trends, aiming to tailor treatment approaches for improved outcomes.
|Market size value in 2021||USD 15.2 billion|
|Market size value in 2030||USD 25.96 billion|
|Forecast Unit (Value)||USD Billion|
|Regions covered||North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)|
Free report customization with purchase. Customization includes:-
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Parent Market Analysis
KEY MARKET INSIGHTS
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
For the Global Idiopathic Pulmonary Fibrosis Treatment Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Global Idiopathic Pulmonary Fibrosis Treatment Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Global Idiopathic Pulmonary Fibrosis Treatment Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Global Idiopathic Pulmonary Fibrosis Treatment Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "
- Mr. Ali Zali, Commercial Director, ICIIC Iran.